

Product datasheet for DM2005

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Osteoprotegerin (TNFRSF11B) Mouse Monoclonal Antibody [Clone ID: OPG-13]

Product data:

Product Type: Primary Antibodies

Clone Name: OPG-13
Applications: ELISA, WB

Recommended Dilution: ELISA.

Western Blot.

Reactivity: Human
Host: Mouse
Isotype: IgG1

Clonality: Monoclonal

Immunogen: Synthetic OPG peptide that comprises AA21 to AA39 homologous with human

osteoprotegerin (N-terminal C has been added to the peptide)

Specificity: The Anti Human Osteoprotegerin, Clone: OPG-13 is a mouse monoclonal antibody against

synthetic peptide of Human Osteoprotegerin.

Formulation: 0.05 M phosphate buffer, 0.1 M NaCl, pH 7.2. AZIDE FREE

State: Aff - Purified

State: Lyophilized purified IgG

Reconstitution Method: Restore with 0.1 ml of deionized water

Concentration: lot specific

Purification: Affinity chromatography on protein G

Conjugation: Unconjugated

Storage: Store lyophilized (preferably in a desiccator) at -20°C and in aliquots at -80°C.

Reconstituted antibody can be stored at 4°C for a limited period of time; it does not show

decline in activity after two weeks at 4°C. Avoid repeated freezing and thawing.

Stability: Shelf life: one year from despatch.

Gene Name: tumor necrosis factor receptor superfamily member 11b

Database Link: Entrez Gene 4982 Human

O00300





Osteoprotegerin (TNFRSF11B) Mouse Monoclonal Antibody [Clone ID: OPG-13] - DM2005

Background: Osteoprotegerin (OPG) or osteoclastogenesis inhibitory factor (OCIF) is a secretory

glycoprotein belonging to TNF receptor superfamily. OPG consists of 401 amino acid residues, it has a molecular weight of 60 kDa as a monomer and 120 kDa as a disulfide-linked dimer and is produced in different tissues, e.g. bone, skin, liver, stomach, intestine and lung. Osteoprotegerin inhibits the recruitment, proliferation and activation of osteoclasts.

Osteoclast formation activity may be monitored principally by determination of

concentration ratio of osteoprotegerin ligand (OPGL)/OPG. Alteration of this ratio may be the

cause of bone loss in many imbalances in bone metabolism such as osteoporosis,

osteopetrosis, hypercalcemia, metastatic osteolytic lesions and rheumatic bone degradation.

Synonyms: OPG, OCIF